Arcturus Therapeutics shares slide 37% in premarket after COVID vaccine data are deemed ‘underwhelming’
December 29, 2020 at 08:57 AM EST
Investors respond to results from a Phase 1/2 trial of its COVID-19 vaccine candidate that one analyst said were disappointing.
